Factors associated with a lack of viral suppression in chronic hbv (CHB) patients after 8 years of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) followed by taf treatment

Gane, Edward J.Buti, MariaFung, Scott K.Chan, Henry Lik YuenIzumi, NamikiChuang, Wan LongAhn, Sang HoonMehta, Rajiv M.Gürel, SelimAbramov, FridaYee, Leland J.Wang, HongyuanMateo, RobertoFlaherty, John F.Ma, XiaoliPan, Calvin Q.Lim, Young-SukMarcellin, Patrick2024-10-152024-10-152023-10-010270-9139https://hdl.handle.net/11452/46446Bu çalışma, 10-14, Kasım 2023 tarihlerinde Boston[Amerika]’da düzenlenen Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) Kongresi‘nde bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/closedAccessGastroenterology & hepatologyFactors associated with a lack of viral suppression in chronic hbv (CHB) patients after 8 years of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) followed by taf treatmentMeeting Abstract001094865401148S519S52078Supplement 1